Biotech | November 30, 2022
Lonza collaborates with AbTis to extend Bioconjugation capabilities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Subscribe To Our Newsletter & Stay Updated
